- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 473/24 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
Patent holdings for IPC class C07D 473/24
Total number of patents in this class: 69
10-year publication summary
|
7
|
7
|
4
|
5
|
6
|
2
|
0
|
2
|
2
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Hoffmann-La Roche Inc. | 3461 |
9 |
| AstraZeneca AB | 2908 |
5 |
| F. Hoffmann-La Roche AG | 7941 |
4 |
| Duke University | 3087 |
4 |
| Dainippon Sumitomo Pharma Co., Ltd. | 190 |
4 |
| Gilead Sciences, Inc. | 2045 |
4 |
| Universite de Liege | 260 |
4 |
| The Regents of the University of California | 20059 |
3 |
| Acea Therapeutics, Inc. | 29 |
3 |
| Janssen Pharmaceutica N.V. | 3369 |
2 |
| Astrocyte Pharmaceuticals, Inc. | 21 |
2 |
| Novartis AG | 10730 |
1 |
| AstraZeneca UK Limited | 633 |
1 |
| Bar-Ilan University | 427 |
1 |
| Curis, Inc. | 131 |
1 |
| Energenesis Biomedical Co., Ltd. | 10 |
1 |
| Handok Pharmaceuticals Co., Ltd. | 10 |
1 |
| Inhibitex, Inc. | 10 |
1 |
| Janus Biotherapeutics, Inc. | 10 |
1 |
| Myriad Genetics, Inc. | 210 |
1 |
| Other owners | 16 |